- Clinical Trials
- April 2025
- 80 Pages
Global
From €1831EUR$2,000USD£1,556GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1831EUR$2,000USD£1,556GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1831EUR$2,000USD£1,556GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1144EUR$1,250USD£972GBP
- Report
- May 2025
- 277 Pages
Global
From €5355EUR$5,850USD£4,551GBP
- Report
- June 2024
- 200 Pages
Global
From €7277EUR$7,950USD£6,185GBP
- Report
- January 2025
- 150 Pages
Global
From €4572EUR$4,995USD£3,886GBP
- Report
- October 2023
- 60 Pages
Global
From €5447EUR$5,950USD£4,629GBP
- Report
- May 2024
- 137 Pages
Global
From €5949EUR$6,499USD£5,056GBP
- Report
- May 2018
- 88 Pages
Global
From €2655EUR$2,900USD£2,256GBP
- Report
- January 2022
- 60 Pages
Global
From €3616EUR$3,950USD£3,073GBP
- Report
- January 2022
- 60 Pages
Global
From €3616EUR$3,950USD£3,073GBP
- Report
- January 2022
- 60 Pages
Global
From €3616EUR$3,950USD£3,073GBP
- Report
- January 2022
- 200 Pages
Global
From €6866EUR$7,500USD£5,835GBP
- Drug Pipelines
- October 2021
- 50 Pages
United States
From €2060EUR$2,250USD£1,750GBP
- Report
- October 2021
- 110 Pages
United States
From €3433EUR$3,750USD£2,917GBP
- Report
- August 2022
Global
From €723EUR$790USD£615GBP
- Report
- February 2024
- 94 Pages
Global
From €3500EUR$4,096USD£3,079GBP
- Report
- June 2023
- 73 Pages
Global
From €3500EUR$4,096USD£3,079GBP
- Report
- August 2022
- 51 Pages
Global
From €1831EUR$2,000USD£1,556GBP

Thrombocytopenic Purpura (TTP) is a rare blood disorder characterized by a low platelet count. It is treated with a variety of hematological drugs, including corticosteroids, immunosuppressants, and anticoagulants. Corticosteroids are used to reduce inflammation and suppress the immune system, while immunosuppressants are used to reduce the body's production of antibodies. Anticoagulants are used to prevent the formation of blood clots. These drugs are used in combination to reduce the risk of bleeding and improve platelet counts.
The market for TTP drugs is highly competitive, with a number of companies offering a range of products. Some of the major players in the market include Pfizer, Novartis, Merck, and Bristol-Myers Squibb. Other companies include AbbVie, AstraZeneca, and Sanofi. These companies offer a range of products, including generic and branded drugs, to meet the needs of patients with TTP. Show Less Read more